133 related articles for article (PubMed ID: 22269936)
1. Layered inorganic nanocomposites: a promising carrier for 5-fluorouracil (5-FU).
Kevadiya BD; Patel TA; Jhala DD; Thumbar RP; Brahmbhatt H; Pandya MP; Rajkumar S; Jena PK; Joshi GV; Gadhia PK; Tripathi CB; Bajaj HC
Eur J Pharm Biopharm; 2012 May; 81(1):91-101. PubMed ID: 22269936
[TBL] [Abstract][Full Text] [Related]
2. Montmorillonite/poly-(ε-caprolactone) composites as versatile layered material: reservoirs for anticancer drug and controlled release property.
Kevadiya BD; Thumbar RP; Rajput MM; Rajkumar S; Brambhatt H; Joshi GV; Dangi GP; Mody HM; Gadhia PK; Bajaj HC
Eur J Pharm Sci; 2012 Aug; 47(1):265-72. PubMed ID: 22525435
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronidase enzyme core-5-fluorouracil-loaded chitosan-PEG-gelatin polymer nanocomposites as targeted and controlled drug delivery vehicles.
Rajan M; Raj V; Al-Arfaj AA; Murugan AM
Int J Pharm; 2013 Sep; 453(2):514-22. PubMed ID: 23796828
[TBL] [Abstract][Full Text] [Related]
4. Layered bionanocomposites as carrier for procainamide.
Kevadiya BD; Joshi GV; Bajaj HC
Int J Pharm; 2010 Mar; 388(1-2):280-6. PubMed ID: 20074630
[TBL] [Abstract][Full Text] [Related]
5. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier.
Jian CH; Lin FH; Lee YH
Biomed Sci Instrum; 2000; 36():391-6. PubMed ID: 10834264
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of clay/poly (L-lactide) microcomposites as anticancer drug, 6-mercaptopurine reservoir through in vitro cytotoxicity, oxidative stress markers and in vivo pharmacokinetics.
Kevadiya BD; Chettiar SS; Rajkumar S; Bajaj HC; Gosai KA; Brahmbhatt H
Colloids Surf B Biointerfaces; 2013 Dec; 112():400-7. PubMed ID: 24036475
[TBL] [Abstract][Full Text] [Related]
7. Ethogel topical formulation for increasing the local bioavailability of 5-fluorouracil: a mechanistic study.
Puri R; Jain S
Anticancer Drugs; 2012 Oct; 23(9):923-34. PubMed ID: 22926258
[TBL] [Abstract][Full Text] [Related]
8. Montmorillonite as a drug delivery system: intercalation and in vitro release of timolol maleate.
Joshi GV; Kevadiya BD; Patel HA; Bajaj HC; Jasra RV
Int J Pharm; 2009 Jun; 374(1-2):53-7. PubMed ID: 19446759
[TBL] [Abstract][Full Text] [Related]
9. Layer-by-layer assembly of poly(L-glutamic acid)/chitosan microcapsules for high loading and sustained release of 5-fluorouracil.
Yan S; Zhu J; Wang Z; Yin J; Zheng Y; Chen X
Eur J Pharm Biopharm; 2011 Aug; 78(3):336-45. PubMed ID: 21195174
[TBL] [Abstract][Full Text] [Related]
10. Long-term and controlled release of chlorhexidine-copper(II) from organically modified montmorillonite (OMMT) nanocomposites.
Wu Y; Zhou N; Li W; Gu H; Fan Y; Yuan J
Mater Sci Eng C Mater Biol Appl; 2013 Mar; 33(2):752-7. PubMed ID: 25427483
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of a novel chitosan/montmorillonite/hydroxyapatite nanocomposite for bone tissue engineering.
Katti KS; Katti DR; Dash R
Biomed Mater; 2008 Sep; 3(3):034122. PubMed ID: 18765898
[TBL] [Abstract][Full Text] [Related]
12. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier.
Lin FH; Lee YH; Jian CH; Wong JM; Shieh MJ; Wang CY
Biomaterials; 2002 May; 23(9):1981-7. PubMed ID: 11996039
[TBL] [Abstract][Full Text] [Related]
13. Overcoming multidrug resistance in 2D and 3D culture models by controlled drug chitosan-graft poly(caprolactone)-based nanoparticles.
Shi WB; Le VM; Gu CH; Zheng YH; Lang MD; Lu YH; Liu JW
J Pharm Sci; 2014 Apr; 103(4):1064-74. PubMed ID: 24523221
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice.
Jin Y; Li J; Rong LF; Lü XW; Huang Y; Xu SY
Acta Pharmacol Sin; 2005 Feb; 26(2):250-6. PubMed ID: 15663907
[TBL] [Abstract][Full Text] [Related]
15. Drug release behavior of chitosan-montmorillonite nanocomposite hydrogels following electrostimulation.
Liu KH; Liu TY; Chen SY; Liu DM
Acta Biomater; 2008 Jul; 4(4):1038-45. PubMed ID: 18337198
[TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of chitosan based thermoreversible gels for intraperitoneal delivery of 5-fluorouracil (5-FU).
Depani BP; Naik AA; Nair HA
Acta Pharm; 2013 Dec; 63(4):479-91. PubMed ID: 24451073
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro models of colorectal carcinoma.
Vilaça N; Amorim R; Machado AF; Parpot P; Pereira MF; Sardo M; Rocha J; Fonseca AM; Neves IC; Baltazar F
Colloids Surf B Biointerfaces; 2013 Dec; 112():237-44. PubMed ID: 23988779
[TBL] [Abstract][Full Text] [Related]
18. Biopolymer/montmorillonite nanocomposite: preparation, drug-controlled release property and cytotoxicity.
Wang X; Du Y; Luo J
Nanotechnology; 2008 Feb; 19(6):065707. PubMed ID: 21730713
[TBL] [Abstract][Full Text] [Related]
19. Intestinal permeability of oxytetracycline from chitosan-montmorillonite nanocomposites.
Salcedo I; Sandri G; Aguzzi C; Bonferoni C; Cerezo P; Sánchez-Espejo R; Viseras C
Colloids Surf B Biointerfaces; 2014 May; 117():441-8. PubMed ID: 24290103
[TBL] [Abstract][Full Text] [Related]
20. Cell proliferation and controlled drug release studies of nanohybrids based on chitosan-g-lactic acid and montmorillonite.
Depan D; Kumar AP; Singh RP
Acta Biomater; 2009 Jan; 5(1):93-100. PubMed ID: 18796355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
